Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (Diluted Average) (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $172.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 17.69% year-over-year to $172.7 million, compared with a TTM value of $172.7 million through Dec 2025, up 17.69%, and an annual FY2025 reading of $172.7 million, up 17.69% over the prior year.
  • Shares Outstanding (Diluted Average) was $172.7 million for Q4 2025 at Xeris Biopharma Holdings, down from $177.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $177.6 million in Q3 2025 and bottomed at $61.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $130.2 million, with a median of $137.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 120.48% in 2022, then grew 1.27% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $79.0 million in 2021, then surged by 71.62% to $135.6 million in 2022, then rose by 1.51% to $137.7 million in 2023, then grew by 6.61% to $146.8 million in 2024, then rose by 17.69% to $172.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for XERS at $172.7 million in Q4 2025, $177.6 million in Q3 2025, and $159.5 million in Q2 2025.